An observational study in Ischemic Stroke and Transient Ischemic Attack, sponsored by Capital Medical University. Recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Capital Medical University · Observational
This study will include the subjects with symptomatic intracranial arterial stenosis (ICAS) who have participated in and completed the 1-year follow-up of RESIST trial (NCT06615726). The aim is to observe the long-term clinical outcomes over 3 years after a 1-year regular physical exercise intervention in patients with symptomatic ICAS.
This is a non-interventional, observational study designed to investigate long-term clinical outcomes in symptomatic ICAS patients who have already enrolled in RESIST trial and completed the 1-year follow-up.
After completing 12-month randomized intervention from RESISR trial, investigators continue to follow the subjects up to 3 years without any further intervention or changes to routine clinical management. The primary endpoint is the incidence of new ischemic stroke within 3 years. Secondary endpoints include new ischemic stroke and transient ischemic attack events in the responsible vessel supply area within 3 years; new ischemic stroke and transient ischemic attack events within 3 years; hemorrhagic stroke event within 3 years; myocardial infarction within 3 years; falls within 3 years; all-cause death within 3 years; the proportion of patients with modified Rankin Scale score 0-1 at 3 years; the score of mini-Montreal Cognitive Assessment at 3 years; and the score of EuroQol 5-Dimension 5-Level at 3 years.
Approximately 1,300 subjects who have completed the RESIST trial's 1-year follow-up and consented to continue will be included. The overall study duration will extend from the first participant's entry into the observation period until the last participant completes the 3-year follow-up.
2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.
This study's planned enrollment of 1,300 is above the median of 300 across 771 observational studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Capital Medical University is the lead sponsor of 295 studies on the registry; 91 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study will include the subjects who enrolled in the RESIST trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who withdrew consent in the RESIST trial, decline to participate in this extension, or were lost to follow-up at 12 months.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with symptomatic ICAS who were assigned to the regular physical exercise intervention in the RESIST trial and completed the 12-month follow-up.
Other: Non-Interventional Study
Participants with symptomatic ICAS who were assigned to the control group in the RESIST trial and completed the 12-month follow-up.
Other: Non-Interventional Study
After completing 12-month intervention from RESIST trial, investigators would not make any interventions or impact on subjects.
New ischemic stroke events
Time frame: Within 3 years after randomization
New ischemic stroke and transient ischemic attack events in the responsible vessel supply area
Time frame: Within 3 years after randomization
New ischemic stroke and transient ischemic attack events
Time frame: Within 3 years after randomization
Hemorrhagic stroke events
Time frame: Within 3 years after randomization
Myocardial infarction events
Time frame: Within 3 years after randomization
Proportion of patients achieving modified Rankin Scale score (mRS) 0-1
The modified Rankin scale (range, 0 \[no symptoms\] to 6 \[death\], with higher scores indicating greater disability)
Time frame: At 3 years after randomization
The score of mini-Montreal Cognitive Assessment
The score of mini-Montreal Cognitive Assessment (range, 0 to 15, with higher scores indicating greater cognition)
Time frame: At 3 years after randomization
Quality of life assessed by EuroQol 5 Dimensions 5 level questionnaire (EQ-5D-5L)
The EQ-5D-5L includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= n
Time frame: At 3 years after randomization
Rate of Falls
Time frame: Within 3 years after randomization
All-cause death
Time frame: Within 3 years after randomization
Plan to share: No — The study is proceeding.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Nov 2028, 34 months after the start.
Of 394 non-industry observational studies under Ischemic Stroke, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 34 months is below that.
Counting every sponsor, half of 436 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.